title: HIV-1 clinical isolates with the E138A substitution in reverse transcriptase show full susceptibility to emtricitabine and other nucleoside reverse transcriptase inhibitors.
authors.affiliation: Gilead Sciences, Inc., Foster City, California, USA danielle.porter@gilead.com.
authors.forename: Danielle P
authors.initials: DP
authors.lastname: Porter
authors.affiliation: Gilead Sciences, Inc., Foster City, California, USA.
authors.forename: Rima
authors.initials: R
authors.lastname: Kulkarni
authors.affiliation: Gilead Sciences, Inc., Foster City, California, USA.
authors.forename: Kirsten L
authors.initials: KL
authors.lastname: White
mesh_terms: D019380:Anti-HIV Agents / Q000494:pharmacology*; D003841:Deoxycytidine / Q000031:analogs & derivatives*; D054303:HIV Reverse Transcriptase / Q000235:genetics* / Q000378:metabolism*; D006801:Humans
chemical_list: D019380:Anti-HIV Agents; D003841:Deoxycytidine; D054303:HIV Reverse Transcriptase